- 中外製薬 press release: 2018.11.16 「当社抗体改変技術に関する米国における特許権侵害訴訟の提起について」
- 米国特許第9,890,377号 claim1: A method of removing an antigen from plasma, the method comprising:
(a) identifying an individual in need of having an antigen removed from the individual's plasma;
(b) providing an antibody that binds to the antigen through the antigen-binding domain of the antibody and has a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 2 to 10,000, when KD is determined using a surface plasmon resonance technique in which the antibody is immobilized, the antigen serves as analyte, and the following conditions are used: 10mM MES buffer, 0.05% polyoxyethylenesorbitan monolaurate, and 150mM NaCl at 37.degree. C.; and
(c) administering the antibody to the individual, wherein the antibody binds to the antigen in plasma in vivo and dissociates from the bound antigen under conditions present in an endosome in vivo, and wherein the antibody is a human IgG or a humanized IgG.